Total Funding
7
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Epiomed Therapeutics is focused on the discovery and development of novel anti-emetic compounds for both the human and veterinary markets.
BARBARA J. COWELL: Attorney-In-Fact for David R. Helton, President Of Issuer- Ernest H. Pfadenhauer: Co-founder & COO
About the Company
Epiomed Therapeutics, Inc. (a Delaware Corporation) was formed in late 2010 based upon technology discovered at Cenomed BioSciences, LLC and assigned to the Epiomed by Cenomed, Inc. The vision of the co-founders (David Helton, Ernest Pfadenhauer and Richard Burgoon) was to establish a drug discovery and development organization with a specific
therapeutic focus, i.e., emesis, and target the intellectual, scientific, human and financial resources of the Company on that focus. This vision further included the objective of going back to the early days of the biopharmaceutical industry targeting the vast majority of the Company financial resources on drug discovery and development, working virtually with limited infrastructure.
